Key Takeaways:
Telix Pharmaceuticals reported H1 revenue of US$477 million, up 22% year-over-year, tracking the upper end of its full-year guidance range.
"The results reflect strong revenue growth, market share gains and significant progress across clinical and regulatory milestones," Managing Director and Group CEO Dr. Christian Behrenbruch said.
Profit after tax reached US$38 million versus a US$2 million loss a year earlier, including US$40 million of other income from a Regeneron collaboration and US$19 million in finance costs tied to refinancing. Adjusted EBITDA rose 146% to US$52 million. The company issued US$600 million of new convertible bonds due 2031 and ended the half with US$252 million in cash and US$23 million of positive operating cash flow.
Precision Medicine revenue climbed 27% to a 65% gross margin, with adjusted segment EBITDA of US$132 million. Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking the upper end of its US$950 million to US$970 million guidance.
Pipeline milestones and regulatory dates
Research and development investment totaled US$124 million, with US$68 million directed to the therapeutics pipeline. The ProstACT Global Part 1 lead-in for TLX591-Tx in metastatic castration-resistant prostate cancer met safety and dosimetry objectives, with the FDA confirming the data supports progression to Part 2. The OPTIMAL-PSMA Phase 2 trial for TLX597-Tx completed enrollment of 120 patients, and the LUTEON registrational trial for TLX250-Tx in advanced clear cell renal cell carcinoma dosed its first patient.
On the imaging side, Pixclara (floretyrosine F 18) for glioma imaging has a PDUFA goal date of September 11, 2026, while its European counterpart Pixlumi had a marketing authorization application validated for review. Illuccix's new drug application is under review by China's NMPA, and Telix continues work toward resubmission of Zircaix's U.S. Biologics License Application after receiving a corrected Complete Response Letter.
The Telix Manufacturing Solutions segment reported US$146 million in total revenue, including US$89 million from third-party sales and US$58 million internal revenue, with an adjusted EBITDA loss widening to US$23 million from US$13 million as the company invests in supply chain and logistics. The Seneffe facility completed its first Good Manufacturing Practice production run of a lutetium-based therapeutic candidate.
Telix also established an at-the-market equity facility with Morgan Stanley and William Blair to issue American Depository Shares on Nasdaq at its discretion, subject to SEC filings and ASX placement capacity. No sales have been made under the facility.
The results give Telix a commercial revenue base that most ASX-listed radiopharmaceutical peers lack, funding three parallel late-stage programs. Investors will watch the September 11 Pixclara PDUFA date and the company's R&D day in New York on September 22 for the next catalysts.
This article is for informational purposes only and does not constitute investment advice.
